Chris Simon/LinkedIn
Mar 6, 2026, 15:09
Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
Chris Simon, President and Chief Executive Officer at Haemonetics, Member of Board of Directors at Sotera Health Company and AdvaMed, shared on LinkedIn:
”Excited to receive FDA clearance for Persona PLUS, our proprietary, patent‑protected plasma apheresis technology.
This next‑generation, donor‑centric innovation advances the NexSys PCS platform, designed to safely improve yield, speed, and donor satisfaction.
Persona PLUS is supported by data from a randomized clinical trial with 30,000 plus donations from approximately 3,000 donors and was developed with our customers for the benefit of patients worldwide, with a clear focus on IgG yield and lowering cost per gram.”
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 21:33J. Meireles-Brandao: Lp(a)HORIZON and the Role of Inflammation in ASCVD
-
Sep 10, 2026, 21:31Alejandro González Veliz: Pregnancy is a Cardiovascular Stress Test
-
Sep 10, 2026, 21:30Tareq Abadl: Did You Know That the Type of Hemoglobin in Our Blood Changes Throughout Life?
-
Sep 10, 2026, 21:30Sumyea Kabir: Apheresis Awareness Day – One Donor, One Procedure, One Therapeutic Difference
-
Sep 10, 2026, 21:30Suhasini Sil: Excited to Share Our New Publication on HLA Beyond Histocompatibility
-
Sep 10, 2026, 21:29Michael Meneghini: Your Calves Are Not Just for Walking
-
Sep 10, 2026, 21:27One month until International Plasma Awareness Week – PPTA Europe
-
Sep 10, 2026, 21:26John Strouse: Supporting Research to Improve Lives in Sickle Cell Disease
-
Sep 10, 2026, 21:23Most Popular Article Award for Thrombophilia Screening – Seminars in Thrombosis and Hemostasis